New clinical trial – Abraxane and carboplatin as first-line treatment for triple negative metastatic breast cancer

Duke University and Abraxis Bioscience recently started a phase II clinical trial involving Abraxane (nanoparticle albumin-bound paclitaxel), now registered in the Clinicaltrials.gov database under reference NCT01207102. The primary objective of the trial is to statistically test whether Abraxane and carboplatin can improve progression-free survival as first-line treatment for “triple negative” (no expression for estrogen, progesterone, or HER2 receptors) metastatic breast cancer. The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

Nanoparticles in clinical trial trends : comments & focus on Abraxane ]]]